ATC Abstracts

American Transplant Congress abstracts

2015 American Transplant Congress » Poster Session B: Clinical Science: Kidney Immunosuppression: Novel Agents

Date: Sunday, May 3, 2015

Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Session Type: Poster Session

Meeting: 2015 American Transplant Congress

5:30pm-6:30pm
A Randomized Cross-Over Phase 3b Study of the Pharmacokinetics of Once-Daily Extended Release MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus in African-Americans (ASERTAA)

J. Trofe-Clark,1,2 D. Brennan,3 P. West-Thielke,4 M. Milone,5 M. Lim,2 R. Bloom.2

5:30pm-6:30pm
Comparison of Pharmacokinetics and Pharmacogenomics of Once-Daily Extended-Release MeltDose® Tacrolimus Tablets (Envarsus® XR) Vs. Twice-Daily Tacrolimus Capsules in Stable African American Kidney Transplant Patients: A Randomized Cross-Over Study

J. Trofe-Clark,1,2 D. Brennan,3 P. West-Thielke,4 M. Milone,5 M. Lim,2 R. Bloom.2

5:30pm-6:30pm
Conversion to Belatacept After Kidney Transplantation Does Not Alter Immunophenotype

M. Matz,1 K. Fabritius,1 C. Lorkowski,1 J. Liu,1 S. Brakemeier,1 N. Unterwalder,2 H.-H. Neumayer,1 K. Budde.1

5:30pm-6:30pm
Customized Reminders and Provider Notification to Improve Adherence to Immunosuppression

P. Reese, R. Bloom, J. Trofe-Clark, A. Mussell, D. Leidy, S. Levsky, J. Zhu, Y. Lin, A. Troxel, H. Feldman, K. Volpp.

5:30pm-6:30pm
Eculizumab as a Rescue Therapy for Rhinovirus-Induced Antibody Mediated Rejection After Incompatible Kidney Transplantation

E. Tantisattamo, A. Shetty, B. Ho, L. Gallon, J. Friedewald.

5:30pm-6:30pm
Efficacy, Safety and Pharmacokinetics of Once-Daily, MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus (Prograf®) in De Novo Kidney Transplant Recipient Sub-Groups: A 2 Year Phase 3 Randomized, Double-Blind, Double-Dummy, Trial

S. Bunnapradist,1 J. Denny,2 M. Waybill,3 P. West-Thielke,4 S. Steinberg.5

5:30pm-6:30pm
Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation

Y. Watarai,1 M. Okada,1 K. Futamura,1 K. Ito,1 T. Yamamoto,1 M. Tsujita,1 T. Hiramitsu,1 N. Goto,1 S. Narumi,1 T. Kobayashi.2

5:30pm-6:30pm
Improved Bioavailability and Reduced Dose Requirements of Novel, Once-Daily, MeltDose® Tacrolimus Formulation Tablets (Envarsus® XR) Compared to Twice-Daily Tacrolimus Capsules (Prograf®) in De Novo Kidney Transplantation: Results of a Phase 3 Double-Dummy, Randomized Trial

J. Grinyó,1 S. Bunnapradist,2 S. Mulgaonkar,3 S. Steinberg.4

5:30pm-6:30pm
Lipid Profiles Over 2 Years Follow-Up in De Novo Kidney Transplant Recipients Randomized to Once-Daily MeltDose® Tacrolimus (Envarsus® XR) Vs. Twice-Daily Tacrolimus (Prograf®): Results from a Phase 3, Double-Blind, Double-Dummy, Multicenter Trial

S. Mulgaonkar, O. Pankewycz, S. Steinberg.

5:30pm-6:30pm
Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy

T. Saavedra,1 O. Opara,1 R. McLoughlin,1 B. Philosophe,2 C. Drachenberg,1 M. Weir,1 S. Bartlett,1 D. Leeser,1 J. Bromberg,1 R. Barth.1

« View all sessions from the 2015 American Transplant Congress